Anti‐Müllerian hormone, a Sertoli cell‐derived marker, is decreased in plasma of male patients in all stages of chronic kidney disease

Publisher： John Wiley & Sons Inc

E-ISSN： 2047-2927|3|6|1160-1164

ISSN： 2047-2919

Source： ANDROLOGY, Vol.3, Iss.6, 2015-11, pp. : 1160-1164

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Serum anti‐Müllerian hormone in subfertile women

By  

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, Vol. 94, Iss. 12, 2015-12 ,pp. : 1307-1312

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Search for a New Marker of Renal Function in Older Patients with Chronic Kidney Disease Stages 3–4: Usefulness of Cystatin C-Based Equations

By  

Nephron Clin Pract, Vol. 112, Iss. 3, 2009-04 ,pp. : c164-c170

Karger

Access to resources Recommend Favorite

The clinical utility of serum anti‐Müllerian hormone in the follow‐up of ovarian adult‐type granulosa cell tumors—A comparative study with inhibin B

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 7, 2015-10 ,pp. : 1661-1671

John Wiley & Sons Inc

Access to resources Recommend Favorite

Follicular and endocrine dose responses according to anti‐Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049)

By  

CLINICAL ENDOCRINOLOGY, Vol. 83, Iss. 6, 2015-12 ,pp. : 902-912

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti‐Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome

By  

CLINICAL ENDOCRINOLOGY, Vol. 88, Iss. 2, 2018-02 ,pp. : 258-262

John Wiley & Sons Inc

Access to resources Recommend Favorite